These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8176640)

  • 1. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.
    Putkonen P; Björling E; Akerblom L; Thorstensson R; Lövgren K; Benthin L; Chiodi F; Morein B; Biberfeld G; Norrby E
    J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):551-9. PubMed ID: 8176640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine protection against HIV-2 infection in cynomolgus monkeys.
    Putkonen P; Thorstensson R; Walther L; Albert J; Akerblom L; Granquist O; Wadell G; Norrby E; Biberfeld G
    AIDS Res Hum Retroviruses; 1991 Mar; 7(3):271-7. PubMed ID: 2064826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of cynomolgus macaques (Macaca fascicularis) against infection with the human immunodeficiency virus type 2 strain ben (HIV-2ben) by immunization with the virion-derived envelope glycoprotein gp130.
    Lüke W; Voss G; Stahl-Hennig C; Coulibaly C; Putkonen P; Petry H; Hunsmann G
    AIDS Res Hum Retroviruses; 1993 May; 9(5):387-94. PubMed ID: 8318267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
    Andersson S; Mäkitalo B; Thorstensson R; Franchini G; Tartaglia J; Limbach K; Paoletti E; Putkonen P; Biberfeld G
    J Infect Dis; 1996 Nov; 174(5):977-85. PubMed ID: 8896498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys.
    Putkonen P; Nilsson C; Walther L; Ghavamzadeh L; Hild K; Broliden K; Biberfeld G; Thorstensson R
    J Med Primatol; 1994; 23(2-3):89-94. PubMed ID: 7966239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.
    Walther-Jallow L; Nilsson C; Söderlund J; Ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
    J Gen Virol; 2001 Jul; 82(Pt 7):1601-1612. PubMed ID: 11413371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
    Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD; Chong P; Klein M; Kieny MP; Paoletti E
    Nat Med; 1995 Apr; 1(4):321-9. PubMed ID: 7585061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic and immunogenic sites of HIV-2 glycoproteins.
    Chiodi F; Björling E; Samuelsson A; Norrby E
    Chem Immunol; 1993; 56():61-77. PubMed ID: 8452654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies.
    Browning M; Reid G; Osborne R; Jarrett O
    Vaccine; 1992; 10(9):585-90. PubMed ID: 1380196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm.
    Nilsson C; Mäkitalo B; Thorstensson R; Norley S; Binninger-Schinzel D; Cranage M; Rud E; Biberfeld G; Putkonen P
    AIDS; 1998 Dec; 12(17):2261-70. PubMed ID: 9863867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines.
    Rimmelzwaan GF; Baars M; van Beek R; van Amerongen G; Lövgren-Bengtsson K; Claas EC; Osterhaus AD
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():757-65. PubMed ID: 9129647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.
    Putkonen P; Thorstensson R; Ghavamzadeh L; Albert J; Hild K; Biberfeld G; Norrby E
    Nature; 1991 Aug; 352(6334):436-8. PubMed ID: 1677743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge.
    Osterhaus A; de Vries P; Morein B; Akerblom L; Heeney J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1507-10. PubMed ID: 1466991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.